Panhematin for Prevention of Acute Attacks of Porphyria

• ClinicalTrials.gov Identifier: NCT02922413
• Recruitment Status: Recruiting
• First Posted: October 4, 2016
• Last Update Posted: February 8, 2023
• Sponsor: The University of Texas Medical Branch, Galveston
• Information provided by (Responsible Party): The University of Texas Medical Branch, Galveston

Study Description

Brief Summary:

The purpose of this study is to determine if Panhematin is safe and effective for prevention of acute attacks of porphyria.

The study aims to provide high quality evidence for the use on hemin for prevention of acute attacks of porphyria. High quality studies have not been done previously for treating or preventing acute attacks with hemin. The lack of strong evidence for efficacy of hemin for treatment and prevention of attacks limits its availability for patients with acute porphyrias. Funding source: FDA Office of Orphan Product Development (FDA OOPD) FD-R-03720

Condition or disease	Intervention/treatment	Phase
Acute Intermittent Porphyria; Hereditary Coproporphyria; Variegate Porphyria	Biological: Hemin for injection; Other: Placebo	Phase 2

Detailed Description:

This is a double-blind, randomized, placebo-controlled, parallel group trial investigating the efficacy and safety of Panhematin™ for preventing acute attacks in at least 20 subjects with well-documented acute porphyria (acute intermittent porphyria, hereditary coproporphyria or variegate porphyria). Subjects will (1.) have had frequent attacks in the past, with symptoms such as abdominal, back and/or limb pain and diagnosed after exclusion of other causes, and (2.) be on hemin prophylaxis for prevention of frequent attacks. It is expected that they will have had 6 or more attacks in one year before starting hemin prophylaxis. This would be considered justification for a preventive regimen of hemin on clinical grounds. Double blind Panhematin™ or placebo will be given. The number of doses will correspond to the number of doses that a subject receives in approximately one week for their prophylactic regimen. An interim analysis will be carried out after completion of 10 subjects to assess progress and possibly adjust the sample size. The trial consists of the following visits:

• A screening visit to determine eligibility and obtain informed consent.
• A treatment visit for administration of double blind prophylactic doses of Panhematin™ or placebo corresponding to the number of doses the subject receives for their prophylactic regimen within approximately one week.
• Follow up visit at 1, 2, 3, and 4 weeks to assess response to the infusion of Panhematin™ or placebo. These visits will be in person or by telephone.
• Additional visits may be scheduled if needed, for example for treatment of symptoms.
• Follow-up visits 3 and 6 months after the end of treatment either in person or by telephone Subjects will have laboratory documentation of one of the acute porphyrias. Molecular documentation is also expected, although rarely a causative mutation cannot be detected. Upon entry into the study they will be given in a blinded fashion one or more preventive doses of either Panhematin™ (4 mg/kg) or placebo, the number of which will correspond to the number of prophylactic doses they have been receiving within approximately one week for prophylaxis. A recurrent attack within the next 1, 2, 3 and 4 weeks will represent treatment failures. Because at study entry most subjects are expected to be on weekly prophylactic hemin treatment, and hemin is a short-acting drug, emphasis in the analysis will be on attacks occurring within 1 week after study treatment.

Any attacks that occur during the study will be treated according to standard of care, which may include Panhematin™, either at the study site or at a subject's usual treatment location.

It is intended that 20 subjects will complete treatment with blinded treatment and at least 4 weeks of follow up. A completed subject is one who meets all entrance criteria, has no exclusion criteria and completes the single dosing and at least one week of follow up, or is withdrawn because of an adverse event.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 20 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Two group parallel blinded study comparing active drug and placebo
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Masking Description: Administered doses are shielded from view. The pharmacy and one nurse who administers the drug intravenously will not be blinded.
• Primary Purpose: Prevention
• Official Title: Safety and Efficacy of Panhematin™ for Prevention of Acute Attacks of Porphyria
• Actual Study Start Date: October 30, 2015
• Estimated Primary Completion Date: January 6, 2024
• Estimated Study Completion Date: January 6, 2025

Arms and Interventions

Arm	Intervention/treatment
Experimental: Hemin for injection; Double blind doses of Panhematin 4 mg/kg body weight reconstituted with 25% human albumin and infused over at least one hour.	Biological: Hemin for injection; Panhematin 4 mg/kg body weight reconstituted with 25% human albumin infused intravenously over at least 1 hour.; Other Name: Hematin
Placebo Comparator: Placebo; A double blind dose of saline.	Other: Placebo; Saline infusion

Outcome Measures

Primary Outcome Measures :

1. Occurrence of an acute attack of porphyria after treatment [ Time Frame: 1-4 weeks ]
   To evaluate in 20 patients who are on a Panhematin™ prophylactic regimen whether blinded administration of Panhematin™ is more effective than placebo in preventing an attack within the next 1-4 weeks. The emphasis will be placed on prevention of attacks in the next week.
2. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 1-4 weeks ]
   To evaluate in 20 patients whether hemin reconstituted with 25% human albumin is as safe and well tolerated as placebo when administered in a blinded fashion. Safety parameters will include the frequency and severity of phlebitis, nausea, vomiting and coagulation abnormalities.

Secondary Outcome Measures :

1. Effects on levels of porphobilinogen [ Time Frame: 1-4 weeks ]
   To evaluate the biochemical effects of Panhematin™ in patients treated with Panhematin™ to prevent attacks of acute porphyria by measuring urinary porphobilinogen and serum porphobilinogen. This will determine whether biochemical measurements are predictive of efficacy in preventing an attack.

Other Outcome Measures:

1. Effects of age [ Time Frame: 1-4 weeks ]
   To evaluate effects of age, as an example of clinical features, on response to preventive administration of Panhematin™.
2. Effects of the nature of the porphobilinogen deaminase (PBGD) mutation [ Time Frame: 1-4 weeks ]
   To evaluate effects of the nature or the PBGD mutation on response to preventive Panhematin™
3. Frequency of injection site complications [ Time Frame: 1-4 weeks ]
   To evaluate the use of Panhematin™ reconstituted with 25% human albumin in patients treated to prevent acute attacks of porphyria in terms of the frequency of injection site complications, which may include thrombosis or inflammation.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male or female aged 18 years
2. Willing to provide written informed consent
3. A diagnosis of acute intermittent porphyria, hereditary coproporphyria or variegate porphyria confirmed by the following criteria, which are based on the criteria for enrollment in the Longitudinal Study of the Porphyrias Consortium. For each type of porphyria, the inclusion criteria are based on 1) clinical features, 2) biochemical findings, as documented by laboratory reports (or copies) of porphyria-specific testing, and 3) molecular studies to identify a mutation in a porphyria-related gene. Equivocal biochemical measurements may require confirmatory testing. Testing for a disease-causing mutation must be attempted, but an identified mutation is not essential for enrollment, since it is known that a mutation cannot be found in a small fraction (<5%) of biochemically proven cases of porphyria. Subjects will (1.) have had frequent attacks in the past, with symptoms such as abdominal, back and/or limb pain and diagnosed after exclusion of other causes, and (2.) be on hemin prophylaxis for prevention of frequent attacks. It is expected that they will have had 6 or more attacks in one year before starting hemin prophylaxis.

Exclusion Criteria:

1. Symptoms such as abdominal, back or limb pain are explained by another condition, as judged by the investigator
2. Known or suspected allergy to Panhematin™ or related products
3. A known or suspected allergy to human albumin
4. Any disease or condition that the investigator judges would lead to an unacceptable risk to the patient or interfere with the successful collection of data for the trial
5. Previous randomization in this trial

Contacts and Locations

Contacts

Contact: Karl E Anderson, MD; 409-772-4661; kanderso@utmb.edu

Contact: Csilla Hallberg, MD; 409-772-4661; ckhallbe@UTMB.EDU

Locations

United States, Texas

University of Texas Medical Branch; Recruiting

Galveston, Texas, United States, 77555

Contact: Karl E Anderson, MD 409-772-4661 kanderso@utmb.edu

Contact: Csilla Hallberg, MD 409-772-4661 ext 24661 ckhallbe@UTMB.EDU

Sponsors and Collaborators

The University of Texas Medical Branch, Galveston

Investigators

• Principal Investigator: Karl E Anderson, MD; University of Texas

  Study Documents (Full-Text)

Documents provided by The University of Texas Medical Branch, Galveston:

Study Protocol and Statistical Analysis Plan  [PDF] June 18, 2019

More Information

• Responsible Party: The University of Texas Medical Branch, Galveston
• ClinicalTrials.gov Identifier: NCT02922413
• Other Study ID Numbers: 14-0188; FD-R-03720 ( Other Grant/Funding Number: FDA - OOPD )
• First Posted: October 4, 2016
• Last Update Posted: February 8, 2023
• Last Verified: February 2023

Keywords provided by The University of Texas Medical Branch, Galveston:

Porphyria; Heme

Additional relevant MeSH terms:

Porphyria, Acute Intermittent; Porphyria, Variegate; Porphyria, Erythropoietic; Porphyrias; Porphyrias, Hepatic; Coproporphyria, Hereditary; Metabolic Diseases; Skin Diseases, Genetic; Genetic Diseases, Inborn; Skin Diseases; Liver Diseases; Digestive System Diseases